BACKGROUND Changes in circulating adiponectin have been related to the risks of various cancers. However, the association between circulating adiponectin and the risk of renal cell carcinoma has not been fully determined. A meta-analysis was performed to evaluate the relationship between circulating adiponectin and renal cell carcinoma risk. METHODS Observational studies that evaluated the association between circulating adiponectin and renal cell carcinoma risk were identified via a systematic search of PubMed and Embase databases. The difference between circulating adiponectin in renal cell carcinoma cases and healthy controls, and the multivariable adjusted association between circulating adiponectin and renal cell carcinoma risk were evaluated. A random effects model was used if significant heterogeneity existed; otherwise a fixed effects model was applied. RESULTS Eight case-control studies with 2624 renal cell carcinoma cases and 2904 healthy controls were included. Pooled results showed that circulating adiponectin was significantly lower in renal cell carcinoma cases than in healthy controls (mean difference = -1.08 ug/mL; 95% confidence interval (CI) -1.62, -0.54; P < 0.001). Higher circulating adiponectin was independently associated with a significantly lowered risk of renal cell carcinoma (adjusted odds ratio for 1 SD increment of adiponectin = 0.78; 95% CI: 0.63, 0.96; P = 0.02). Subgroup analyses according to characteristics including study design, ethnics of participants, blood samples, numbers of participants, mean ages of participants, and study quality showed consistent results. CONCLUSIONS Lower circulating adiponectin is associated with increased risk of renal cell carcinoma. The potential pathophysiological mechanisms underlying the role of circulating adiponectin in the pathogenesis of renal cell carcinoma deserve further investigation.

中文翻译：

---

较低的循环脂联素与较高的肾细胞癌风险相关：一项荟萃分析。

背景循环脂联素的变化与各种癌症的风险有关。然而，循环脂联素与肾细胞癌风险之间的关联尚未完全确定。进行荟萃分析以评估循环脂联素与肾细胞癌风险之间的关系。方法 通过对 PubMed 和 Embase 数据库的系统搜索，确定了评估循环脂联素与肾细胞癌风险之间关联的观察性研究。评估了肾细胞癌病例和健康对照中循环脂联素的差异，以及循环脂联素与肾细胞癌风险之间的多变量调整关联。如果存在显着的异质性，则使用随机效应模型；否则应用固定效应模型。结果 纳入 8 项病例对照研究，包括 2624 例肾细胞癌病例和 2904 例健康对照。汇总结果显示，肾细胞癌病例的循环脂联素显着低于健康对照组（平均差 = -1.08 ug/mL；95% 置信区间 (CI) -1.62，-0.54；P < 0.001）。较高的循环脂联素与肾细胞癌风险显着降低独立相关（脂联素每增加 1 个标准差的调整优势比 = 0.78；95% CI：0.63，0.96；P = 0.02）。根据研究设计、参与者的种族、血液样本、参与者人数、参与者的平均年龄和研究质量等特征进行的亚组分析显示出一致的结果。结论 较低的循环脂联素与肾细胞癌风险增加相关。循环脂联素在肾细胞癌发病机制中的潜在病理生理机制值得进一步研究。